Inactive Instrument

Highlights Endologix, Inc. Nasdaq

Equities

US29266S1069

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Endologix LLC Announces the U. S. Centers for Medicare & Medicaid Services Grants Transitional Pass-Through Payment for the Detour System	Dec. 27	CI
Endologix Announces Results of Pooled Analysis of DETOUR1 and DETOUR2 Studies at 2023 VIVA Late-Breaking Clinical Trial Session	Nov. 02	CI
Endologix Llc Announces the U. S. Centers for Medicare & Medicaid Services Grants New Technology Add-On Payment for the Detour System	23-09-07	CI
Endologix Announces First Patients Treated with the DETOUR?? System, Advancing Treatment for Complex Peripheral Artery Disease	23-07-18	CI
Endologix LLC Announces 24-Month Results of DETOUR-2 Study at 2023 Vascular Annual Meeting	23-06-15	CI
Endologix Llc Receives Fda Approval of the Detour System to Treat Long Complex Superficial Femoropopliteal Lesions in Patients with Pad	23-06-08	CI
Endologix LLC Announces 150Th Patient Enrolled in JAGUAR Randomized Controlled Trial	23-05-23	CI
Endologix Announces 12-Month Results of DETOUR-2 Trial at 2022 VIVA Late-Breaking Clinical Trial Session	22-11-11	CI
Endologix LLC Announced the Five-Year Results from the Leopard Randomized Controlled Trial	22-11-03	CI
Endologix LLC Announces the Elevate	22-10-20	CI
Endologix LLC Submits Premarket Approval Application to FDA for the DETOUR System	22-10-10	CI
Endologix Reports 12 Month Data from DETOUR 2 Clinical Trial at 2022 Vascular Annual Meeting	22-06-23	CI
Endologix Announces Completion of Enrollment in the TORUS 2 Study for PAD in SFA	21-11-23	CI
Endologix LLC Initiates Randomized Study of ALTO® Abdominal Stent Graft System	21-09-29	CI
Endologix Llc Receives U.S. Food and Drug Administration Breakthrough Device Designation for ChEVAS System	21-07-19	CI
Endologix Llc Announces Launch of Alto Abdominal Stent Graft System in Canada and Argentina	21-05-11	CI
Endologix, Inc. acquired PQ Bypass, Inc. for approximately $300 million.	21-04-12	CI
Endologix Announces First Commercial Implant of ALTO Abdominal Stent Graft System Outside of United States	20-09-02	CI
Endologix, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-10	CI
Endologix Receives CE Mark for ALTO Abdominal Stent Graft System	20-08-05	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Endologix, Inc. Nasdaq

Equities

US29266S1069

Highlights

Filters